サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1435148

肥満症治療薬市場：治療タイプ別、最終用途別-2024-2030年の世界予測

Anti-Obesity Therapeutics Market by Treatment Type (Medications, Treatments), End-use (Ambulatory Surgical Centers, Hospitals, Specialty Clinics) - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
肥満症治療薬市場：治療タイプ別、最終用途別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

肥満症治療薬市場規模は2023年に99億8,000万米ドルと推計され、2024年には108億1,000万米ドルに達し、CAGR 8.44%で2030年には176億米ドルに達すると予測されます。

肥満症治療薬の世界市場

主な市場の統計
基準年[2023］ 99億8,000万米ドル
予測年[2024］ 108億1,000万米ドル
予測年 [2030] 176億米ドル
CAGR（%） 8.44%
肥満症治療薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは肥満症治療薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、肥満症治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-肥満症治療薬市場の市場規模および予測は？

2-肥満症治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-肥満症治療薬市場における技術動向と規制の枠組みは？

4-肥満症治療薬市場における主要ベンダーの市場シェアは？

5-肥満症治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 肥満および関連疾患の発生率の増加
      • 運動不足による座りっぱなしのライフスタイルの増加
      • 新規抗肥満薬のイントロダクション
    • 抑制要因
      • 肥満症治療薬の副作用（精神障害や脳卒中など）のリスク
    • 機会
      • 進行中の臨床試験および研究開発活動
      • 臨床的に重大な体重減少に関連する薬物標的の数の増加
    • 課題
      • 体重管理に関する知識が限られている
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 肥満症治療薬市場治療タイプ別

  • 薬
    • ブプロピオン-ナルトレキソン
    • リラグルチド
    • オルリファスト
    • フェンテルミン-トピラマート
    • セマグルチド
  • 治療法
    • 調節可能な胃バンディング
    • 内視鏡スリーブ胃形成術
    • 胃バイパス手術

第7章 肥満症治療薬市場：最終用途別

  • 外来手術センター
  • 病院
  • 専門クリニック

第8章 南北アメリカの肥満症治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の肥満症治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの肥満症治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Currax Pharmaceuticals LLC
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline PLC
    • Merck & Co., Inc.
    • Norgine B.V.
    • Novartis AG
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Rhythm Pharmaceuticals, Inc.
    • SHIONOGI & Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • Vivus LLC
  • 主要な製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANTI-OBESITY THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTI-OBESITY THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 8. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 10. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTI-OBESITY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 8. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 15. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 19. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 190. ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 191. ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. ANTI-OBESITY THERAPEUTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-EC2E133E33FA

[180 Pages Report] The Anti-Obesity Therapeutics Market size was estimated at USD 9.98 billion in 2023 and expected to reach USD 10.81 billion in 2024, at a CAGR 8.44% to reach USD 17.60 billion by 2030.

Global Anti-Obesity Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 9.98 billion
Estimated Year [2024] USD 10.81 billion
Forecast Year [2030] USD 17.60 billion
CAGR (%) 8.44%
Anti-Obesity Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anti-Obesity Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-Obesity Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anti-Obesity Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc., Norgine B.V., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals, Inc., SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vivus LLC.

Market Segmentation & Coverage

This research report categorizes the Anti-Obesity Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment Type
    • Medications
      • Bupropion-naltrexone
      • Liraglutide
      • Orlistat
      • Phentermine-topiramate
      • Semaglutide
    • Treatments
      • Adjustable Gastric Banding
      • Endoscopic Sleeve Gastroplasty
      • Gastric Bypass Surgery
  • End-use
    • Ambulatory Surgical Centers
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Anti-Obesity Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-Obesity Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Anti-Obesity Therapeutics Market?

4. What is the market share of the leading vendors in the Anti-Obesity Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Anti-Obesity Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Anti-Obesity Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of obesity and related disorder
      • 5.1.1.2. Rising adoption of sedentary lifestyle due to lack of exercise
      • 5.1.1.3. Introduction of novel anti-obesity drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of side effects of anti-obesity therapeutics such as psychiatric disorder as well as strokes
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing clinical trials and research & development activities
      • 5.1.3.2. Increasing number of drug targets associated with clinically significant weight loss
    • 5.1.4. Challenges
      • 5.1.4.1. Limited of knowledge regarding weight management
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Anti-Obesity Therapeutics Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Medications
    • 6.3.1. Bupropion-naltrexone
    • 6.3.2. Liraglutide
    • 6.3.3. Orlistat
    • 6.3.4. Phentermine-topiramate
    • 6.3.5. Semaglutide
  • 6.3. Treatments
    • 6.4.1. Adjustable Gastric Banding
    • 6.4.2. Endoscopic Sleeve Gastroplasty
    • 6.4.3. Gastric Bypass Surgery

7. Anti-Obesity Therapeutics Market, by End-use

  • 7.1. Introduction
  • 7.2. Ambulatory Surgical Centers
  • 7.3. Hospitals
  • 7.4. Specialty Clinics

8. Americas Anti-Obesity Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Anti-Obesity Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Anti-Obesity Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Boehringer Ingelheim International GmbH
    • 12.1.2. Bristol-Myers Squibb Company
    • 12.1.3. Currax Pharmaceuticals LLC
    • 12.1.4. Eisai Co., Ltd.
    • 12.1.5. Eli Lilly and Company
    • 12.1.6. F. Hoffmann-La Roche Ltd.
    • 12.1.7. GlaxoSmithKline PLC
    • 12.1.8. Merck & Co., Inc.
    • 12.1.9. Norgine B.V.
    • 12.1.10. Novartis AG
    • 12.1.11. Novo Nordisk A/S
    • 12.1.12. Pfizer Inc.
    • 12.1.13. Rhythm Pharmaceuticals, Inc.
    • 12.1.14. SHIONOGI & Co., Ltd.
    • 12.1.15. Takeda Pharmaceutical Company Limited
    • 12.1.16. Vivus LLC
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing